Thad Allen Huston Sells 2,000 Shares of LivaNova PLC (NASDAQ:LIVN) Stock

Share on StockTwits

LivaNova PLC (NASDAQ:LIVN) CFO Thad Allen Huston sold 2,000 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $75.00, for a total value of $150,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of LIVN stock opened at $72.76 on Wednesday. LivaNova PLC has a twelve month low of $64.80 and a twelve month high of $131.54. The stock has a market cap of $3.65 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 3.18 and a beta of 0.61. The stock has a fifty day moving average price of $72.61. The company has a quick ratio of 0.61, a current ratio of 0.87 and a debt-to-equity ratio of 0.13.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 1st. The company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.11. The business had revenue of $250.80 million during the quarter, compared to analysts’ expectations of $254.89 million. LivaNova had a positive return on equity of 9.38% and a negative net margin of 19.64%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.68 EPS. Analysts forecast that LivaNova PLC will post 2.6 EPS for the current fiscal year.

LIVN has been the subject of several research reports. BidaskClub cut LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. ValuEngine cut LivaNova from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Needham & Company LLC reiterated a “buy” rating and issued a $87.00 target price on shares of LivaNova in a report on Wednesday, May 15th. Stifel Nicolaus reiterated a “buy” rating and issued a $100.00 target price on shares of LivaNova in a report on Friday, April 5th. Finally, BTIG Research reiterated a “hold” rating on shares of LivaNova in a report on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $106.40.

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. Norges Bank purchased a new stake in shares of LivaNova during the 4th quarter worth $46,478,000. JPMorgan Chase & Co. lifted its stake in shares of LivaNova by 31.5% during the 1st quarter. JPMorgan Chase & Co. now owns 647,760 shares of the company’s stock worth $62,995,000 after purchasing an additional 155,079 shares during the last quarter. Gotham Asset Management LLC purchased a new stake in shares of LivaNova during the 4th quarter worth $13,750,000. BlackRock Inc. lifted its stake in shares of LivaNova by 2.2% during the 4th quarter. BlackRock Inc. now owns 5,915,599 shares of the company’s stock worth $541,101,000 after purchasing an additional 127,669 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its stake in shares of LivaNova by 99.5% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 240,600 shares of the company’s stock worth $23,398,000 after purchasing an additional 120,000 shares during the last quarter. Hedge funds and other institutional investors own 84.37% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

Featured Story: How is an ETF different from a mutual fund?

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.